Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the bioequivalence of Mylan's alendronate
sodium 10 mg tablets to Merck's Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10
mg) dose administration under fasting conditions.